Advancing Human Health Through Science

Biocentra is a US-based pharmaceutical company committed to developing innovative therapies that improve lives worldwide.

Explore Products Our Pipeline

0 Years of Research

0 Active Compounds

0 FDA Approvals

0 Countries

FDA Approved WHO GMP Certified ISO 9001:2015 cGMP Compliant

Our Therapeutic Areas

We focus on areas of greatest unmet medical need, leveraging cutting-edge science to develop breakthrough therapies.

Oncology

Advancing targeted therapies and immunotherapies to combat cancer at its source. Our pipeline includes novel small molecules and biologics for solid tumors and hematologic malignancies.

Cardiovascular

Developing next-generation treatments for heart disease, hypertension, and lipid disorders with a focus on improving long-term patient outcomes and quality of life.

Neurology

Pioneering treatments for neurodegenerative disorders including Alzheimer's, Parkinson's, and multiple sclerosis through innovative approaches to neural repair and protection.

View All Products

Why Choose Biocentra

Our commitment to excellence drives everything we do, from research to delivery.

A Trusted Partner in Global Healthcare

With over 15 years of dedicated research and development, Biocentra has established itself as a leading force in the pharmaceutical industry. Our state-of-the-art facilities and world-class team ensure that every therapy we develop meets the highest standards of safety, efficacy, and quality.

From our headquarters in New York to our research centers across the United States, we are united by a single mission: to advance human health through innovative science.

FDA-Registered Facilities

All our facilities meet or exceed FDA standards for pharmaceutical manufacturing and research.

Cutting-Edge R&D

Investing over $500 million annually in research to discover and develop breakthrough therapies.

Global Distribution

Reaching patients in 12 countries across North America, Europe, and Asia with reliable supply chains.

Patient-First Approach

Every decision we make is guided by our commitment to improving patient outcomes and quality of life.

Our Pipeline

From discovery to FDA review, our pipeline reflects our commitment to innovation.

Discovery 12

Pre-Clinical 8

Phase I 6

Phase II 4

Phase III 2

FDA Review 0

View Full Pipeline

What Medical Professionals Say

Hear from healthcare leaders who partner with Biocentra.

"Biocentra's commitment to rigorous clinical research sets them apart. Their oncology pipeline represents some of the most promising therapies I've seen in my 20-year career."

Dr. Robert Jennings

Chief of Oncology, Massachusetts General Hospital

"The cardiovascular treatments developed by Biocentra have transformed outcomes for my patients with resistant hypertension. Their patient-first approach is truly commendable."

Dr. Michelle Kwon

Director of Cardiology, Cleveland Clinic

"As a neurologist, I've been impressed by the science behind Biocentra's neurodegenerative disease program. They are tackling some of the most challenging conditions with real innovation."

Dr. Aaron Thompson

Professor of Neurology, Johns Hopkins Medicine

Latest News

Stay informed about the latest developments at Biocentra.

Research December 15, 2025

BCT-104 Shows Promising Results in Phase II Trial for Non-Small Cell Lung Cancer

Biocentra announces positive top-line results from its Phase II clinical trial evaluating BCT-104 in patients with advanced NSCLC, demonstrating a 42% reduction in tumor burden.

FDA Update November 28, 2025

FDA Grants Fast Track Designation to BCT-107 for Alzheimer's Disease

The U.S. Food and Drug Administration has granted Fast Track designation to Biocentra's BCT-107, a novel therapeutic candidate for early-stage Alzheimer's disease.

Company News October 10, 2025

Biocentra Expands Research Operations with New Jersey Innovation Center

Biocentra cuts the ribbon on a new 120,000-square-foot research facility in Bridgewater, New Jersey, creating 300 new high-skilled jobs in the region.